|Bid||20.93 x 1000|
|Ask||0.00 x 1200|
|Day's Range||20.51 - 21.65|
|52 Week Range||18.12 - 57.21|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.57|
NEW YORK, NY / ACCESSWIRE / April 23, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
New Orleans, Louisiana--(Newsfile Corp. - April 22, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in a securities class action lawsuit against FibroGen, Inc. (NASDAQ: FGEN), if they purchased the Company's securities and/or sold put options between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). ...
RADNOR, PA / ACCESSWIRE / April 22, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ:FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put optionsfrom November 8, 2019 through April 6, 2021, inclusive (the "Class Period").